Suchergebnisse - "Davies, Jane C"

PubPharm (14)

1

Improvement in Lung Clearance Index and Chest Computed Tomography Scores with Elexacaftor/Tezacaftor/Ivacaftor Treatment in People with Cystic Fibrosis Aged 12 Years and Older - The RECOVER Trial

enthalten in: American journal of respiratory and critical care medicine | 2023

von McNally, P. | Lester, K. | Stone, G. | +25

CommentIn: Am J Respir Crit Care Med. 2023 Nov 1;208(9):911-913. - PMID 37756441

2

Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged ⩾6 Years with Cystic Fibrosis and at Least One F508del Allele : A Phase 3, Open-Label Clinical Trial

enthalten in: American journal of respiratory and critical care medicine | 2023

von Wainwright, C. | McColley, S. | McNally, P. | +14

CommentIn: Am J Respir Crit Care Med. 2023 Jul 1;208(1):9-11. - PMID 37167625

3

Raised Intracranial Pressure in Three Children with Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-Ivacaftor Modulator Therapy

enthalten in: American journal of respiratory and critical care medicine | 2023

von Southern, K. | Barben, J. | Goldring, S. | +5

4

Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation : A Phase 3b, Randomized, Placebo-controlled Study

enthalten in: American journal of respiratory and critical care medicine | 2022

von Mall, M. | Brugha, R. | Gartner, S. | +21

CommentIn: Am J Respir Crit Care Med. 2022 Dec 1;206(11):1308-1310. - PMID 35947636

5

A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children ≥ 6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variant

enthalten in: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society | 2022

von Sawicki, G. | Chilvers, M. | McNamara, J. | +10

6

An Update on CFTR Modulators as New Therapies for Cystic Fibrosis

enthalten in: Paediatric drugs | 2022

von King, J. | Nichols, A. | Bentley, S. | +2

7

Long-term safety and efficacy of lumacaftor-ivacaftor therapy in children aged 6-11 years with cystic fibrosis homozygous for the F508del-CFTR mutation : a phase 3, open-label, extension study

enthalten in: The Lancet. Respiratory medicine | 2021

von Chilvers, M. | Davies, J. | Milla, C. | +5

ErratumIn: Lancet Respir Med. 2021 Apr;9(4):e38. - PMID 33607008

8

Entering the era of highly effective modulator therapies

enthalten in: Pediatric pulmonology | 2021

von Dave, K. | Dobra, R. | Scott, S. | +4

9

A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation

enthalten in: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society | 2021

von Davies, J. | Sermet-Gaudelus, I. | Naehrlich, L. | +10

10

VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

enthalten in: The New England journal of medicine | 2018

von Davies, J. | Moskowitz, S. | Brown, C. | +61

CommentIn: N Engl J Med. 2018 Oct 25;379(17):1671-1672. - PMID 30334694